Skip to content
Research Article Open access CC BY 3.0

Effects of Co-infusion of Plasma, Whole Blood and Anticogulants on Their Clotting Activities

Hiroshi Fujita, Yumiko Ishihama, Shigeko Nishimura

International Blood Research & Reviews · pp. 87–94 · Published 20 Feb 2014

10.9734/IBRR/2014/8146

Abstract

Aims: Nafamostat mesilate (NM), a protease inhibitor is available for treating acute pancreatitis and disseminated intravascular coagulopathy and it is used as an anticoagulant for hemodialysis in Japan. A plasmapheresis circuit using NM can easily be blockaded. Therefore, we investigated the influence of co-infusion of fresh frozen plasma (FFP), whole blood and NM on clotting activities mainly in the static condition compared with other anticoagulants including heparin sodium and gabexate mesilate. Study Design:  In vitro study. Methodology: We investigated the effect of co-incubation of expired FFP and various concentrations of NM (0–0.1mg/mL). We measured the plasma fibrinogen level and activities of factor XIII, anti-thrombin III, protein C (PC) and protein S (PS). In addition, we examined the influence of NM on coagulation tests using whole blood from healthy volunteers. Results: NM reduced PC and PS activities in FFP, although it did not affect plasma fibrinogen levels or the activities of anti-thrombin III or factor XIII. While anti-thrombin III activity and plasma fibrinogen level increased in NM-containing whole blood, PC and PS activities decreased. Gabexate mesilate, sodium heparin and citrate did not reduce the activities of PC or PS. Conclusion: Co-infusion of FFP, whole blood and NM reduces PC and PS activities and we speculate that it may lead to the obstruction of the plasmapheresis circuit when using NM as an anticoagulant.  

Co-infusion protease inhibitor protein C protein S

References (15)

  1. 1 New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin [DOI]
  2. 2 Prevalence of thrombophilia according to age at the first manifestation of venous thromboembolism: results from the MAISTHRO registry [DOI]
  3. 3 Use of Nafamostat Mesilate as an Anticoagulant during Extracorporeal Membrane Oxygenation [DOI]
  4. 4 Gabexate Mesilate, a Synthetic Protease Inhibitor, Inhibits Lipopolysaccharide-Induced Tumor Necrosis Factor-α Production by Inhibiting Activation of Both Nuclear Factor-κB and Activator Protein-1 in Human Monocytes [DOI]
  5. 5 Compatibility of Common Intravenous Solutions with CPD Blood [DOI]
  6. 6 Protein S binding to human endothelial cells is required for expression of cofactor activity for activated protein C. [DOI]
  7. 7 Anticoagulation with Nafamostat Mesilate, a Synthetic Protease Inhibitor, in Hemodialysis Patients with a Bleeding Risk [DOI]
  8. 8 Extracorporeal membrane oxygenation with nafamostat mesilate as an anticoagulant for massive pulmonary hemorrhage after living-donor lobar lung transplantation [DOI]
  9. 9 Co-Administration of Drugs and Blood Products [DOI]
  10. 10 The effect of patient‐controlled analgesia on coadministered red blood cells [DOI]
  11. 11 Nafamostat Mesilate, a Broad Spectrum Protease Inhibitor, Modulates Platelet, Neutrophil and Contact Activation in Simulated Extracorporeal Circulation [DOI]
  12. 12 Ringer’s lactate is compatible with saline-adenine-glucose-mannitol preserved packed red blood cells for rapid transfusion [DOI]
  13. 13 Drugs and blood transfusions: dogma‐ or evidence‐based practice? [DOI]
  14. 14 Feasibility of a new in vitro approach to evaluate cellular damage following co-infusion of red blood cell concentrates and intravenous drug solutions [DOI]
  15. 15 Nafamostat mesilate, a noncalcium compound, as an anticoagulant, induces calcium‐dependent haemolysis when infused with packed erythrocytes [DOI]

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

70

Page views

0

PDF downloads

21

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.